# Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

> **NCT00450463** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 64 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Sargramostim (GM-CSF, Leukine)
- **DRUG:** Flutamide (Eulexin)
- **BIOLOGICAL:** PROSTVAC-F/ TRICOM
- **BIOLOGICAL:** PROSTVAC-V/TRICOM

## Key facts

- **NCT ID:** NCT00450463
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-23
- **Primary completion:** 2017-04-27
- **Final completion:** 2017-06-08
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450463, "Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00450463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*